Targeted Quantification of Phosphorylation Dynamics in the Context of EGFR-MAPK Pathway

被引:34
|
作者
Yi, Lian [1 ]
Shi, Tujin [1 ]
Gritsenko, Marina A. [1 ]
Chan, Chi-Yuet X'avia [1 ]
Fillmore, Thomas L. [2 ]
Hess, Becky M. [3 ]
Swensen, Adam C. [1 ]
Liu, Tao [1 ]
Smith, Richard D. [1 ,2 ]
Wiley, H. Steven [2 ]
Qian, Wei-Jun [1 ]
机构
[1] Pacific Northwest Natl Lab, Biol Sci Div, Richland, WA 99352 USA
[2] Pacific Northwest Natl Lab, Environm Mol Sci Lab, Richland, WA 99352 USA
[3] Pacific Northwest Natl Lab, Signatures Sci & Technol Div, Richland, WA 99352 USA
关键词
TYROSINE PHOSPHORYLATION; ENRICHMENT; REVEALS; CANCER; CELLS; PHOSPHOPROTEOMICS; PROTEOMICS; PROTEINS; KINASES; GROWTH;
D O I
10.1021/acs.analchem.8b00071
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Large-scale phosphoproteomics with coverage of over 10,000 sites of phosphorylation have now been routinely achieved with advanced mass spectrometry (MS)-based workflows. However, accurate targeted MS-based quantification of phosphorylation dynamics, an important direction for gaining quantitative understanding of signaling pathways or networks, has been much less investigated. Herein, we report an assessment of the targeted workflow in the context of signal transduction pathways, using the epidermal growth factor receptor (EGFR)-mitogen-activated protein kinase (MAPK) pathway as our model. A total of 43 phosphopeptides from the EGFR-MAPK pathway were selected for the study. The recovery and sensitivity of two commonly used enrichment methods, immobilized metal affinity chromatography (IMAC) and titanium oxide (TiO2), combined with selected reaction monitoring (SRM)-MS were evaluated. The recovery of phosphopeptides by IMAC and TiO2 enrichment was quantified to be 38 +/- 5% and 58 +/- 20%, respectively, based on internal standards. Moreover, both enrichment methods provided comparable sensitivity from 1 to 100 mu g starting peptides. Robust quantification was consistently achieved for most targeted phosphopeptides when starting with 25-100 mu g peptides. However, the numbers of quantified targets significantly dropped when peptide samples were in the 1-25 mu g range. Finally, IMAC-SRM was applied to quantify signaling dynamics of EGFR-MAPK pathway in Hs578T cells following 10 ng/mL EGF treatment. The kinetics of phosphorylation clearly revealed early and late phases of phosphorylation, even for very low abundance proteins. These results demonstrate the feasibility of robust targeted quantification of phosphorylation dynamics for specific pathways, even starting with relatively small amounts of protein.
引用
收藏
页码:5256 / 5263
页数:8
相关论文
共 50 条
  • [1] EGFR-MAPK pathway activation in human papillomavirus infected cells
    Barraza, Pamela
    Ozbun, Michelle
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [2] From pathway to population - a multiscale model of juxtacrine EGFR-MAPK signalling
    Walker, D. C.
    Georgopoulos, N. T.
    Southgate, J.
    [J]. BMC SYSTEMS BIOLOGY, 2008, 2
  • [3] Conservation of protein abundance patterns reveals the regulatory architecture of the EGFR-MAPK pathway
    Shi, Tujin
    Niepel, Mario
    McDermott, Jason E.
    Gao, Yuqian
    Nicora, Carrie D.
    Chrisler, William B.
    Markillie, Lye M.
    Petyuk, Vladislav A.
    Smith, Richard D.
    Rodland, Karin D.
    Sorger, Peter K.
    Qian, Wei-Jun
    Wiley, H. Steven
    [J]. SCIENCE SIGNALING, 2016, 9 (436)
  • [4] Cortactin promotes colorectal cancer cell proliferation by activating the EGFR-MAPK pathway
    Zhang, Xiaojian
    Liu, Kun
    Zhang, Tao
    Wang, Zhenlei
    Qin, Xuan
    Jing, Xiaoqian
    Wu, Haoxuan
    Ji, Xiaopin
    He, Yonggang
    Zhao, Ren
    [J]. ONCOTARGET, 2017, 8 (01) : 1541 - 1554
  • [5] Cucurbitacin IIa interferes with EGFR-MAPK signaling pathway leads to proliferation inhibition in A549 cells
    Zhang, Jie
    Song, Yifan
    Liang, Yuan
    Zou, Haoyang
    Zuo, Peng
    Yan, Mi
    Jing, Siyuan
    Li, Tiezhu
    Wang, Yongjun
    Li, Da
    Zhang, Tiehua
    Wei, Zhengyi
    [J]. FOOD AND CHEMICAL TOXICOLOGY, 2019, 132
  • [6] Estrone analogs as potential inhibitors targeting EGFR-MAPK pathway in non-small-cell lung cancer
    Acheampong, Felix
    Ostlund, Trevor
    Mahnashi, Mater
    Halaweish, Fathi
    [J]. CHEMICAL BIOLOGY & DRUG DESIGN, 2023, 101 (06) : 1356 - 1366
  • [7] Regulation of Hippo Signaling by EGFR-MAPK Signaling through Ajuba Family Proteins
    Reddy, B. V. V. G.
    Irvine, Kenneth D.
    [J]. DEVELOPMENTAL CELL, 2013, 24 (05) : 459 - 471
  • [8] Novel EGFR-MAPK kinase and ABC transporter inhibitors for HepG2 resistant to Erlotinib
    Ostlund, Trevor
    SutraDhar, Kakan
    Elgazwi, Sara M. M.
    Mahnashi, Mater
    Kyeremateng, Jennifer
    Iram, Surtaj
    Halaweish, Fathi
    [J]. DRUG DEVELOPMENT RESEARCH, 2023, 84 (02) : 200 - 210
  • [9] Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC
    Rong, Chao
    Muller, Marie F.
    Xiang, Fang
    Jensen, Alexandra
    Weichert, Wilko
    Major, Gerald
    Plinkert, Peter K.
    Hess, Jochen
    Affolter, Annette
    [J]. BRITISH JOURNAL OF CANCER, 2020, 123 (02) : 288 - 297
  • [10] Dual Wnt and EGFR-MAPK dependency of BRAFV600E-mutant colorectal cancer
    Wang, Youzhen
    Palmer, Michael
    Jaeger, Savina
    Bagdasarian, Linda
    Qiu, Shumei
    Woolfenden, Steve
    Meyer, Ronald
    Yang, Guizhi
    Green, John
    Pan, Shifeng
    Liu, Jun
    Gao, Hui
    Cao, Z. Alexander
    Myers, Andrea
    McLaughlin, Margaret E.
    [J]. CANCER RESEARCH, 2015, 75